Treatment of parasitic diarrhea in HIV-infected patients

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 3, 2008, Pages 337-349

  Derouin, Francis ^a   Lagrange Xelot, Marie ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

AIDS; Blastocystis; Cryptosporidium; Cyclospora; Diarrhea; Giardia; Highly active antiretroviral therapy; Isospora; Microsporidia; Protozoa

Indexed keywords

ALBENDAZOLE; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIIODOHYDROXYQUIN; FLISINT; FOLINIC ACID; FUMAGILLIN; IVERMECTIN; MACROLIDE; METRONIDAZOLE; NITAZOXANIDE; PAROMOMYCIN; PLACEBO; PROTEINASE INHIBITOR; PYRIMETHAMINE; RIFABUTIN; RITONAVIR; ROXITHROMYCIN; SPIRAMYCIN; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT;

AMEBIASIS; ANTIPROTOZOAL ACTIVITY; BLASTOCYSTIS HOMINIS; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CLINICAL TRIAL; COCCIDIOSIS; CRYPTOSPORIDIOSIS; CYCLOSPORA; CYCLOSPORIASIS; DIARRHEA; DIENTAMOEBA; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENTAMOEBA HISTOLYTICA; ERADICATION THERAPY; FECES ANALYSIS; GIARDIA LAMBLIA; GIARDIASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROSPORIDIOSIS; NEUTROPENIA; NONHUMAN; PARASITE CONTROL; PARASITE TRANSMISSION; PARASITOSIS; REHYDRATION; REVIEW; SARCOMASTIGOPHORA INFECTION; SINGLE DRUG DOSE; STRONGYLOIDIASIS; THROMBOCYTOPENIA; TRANSMISSION ELECTRON MICROSCOPY; AIDS RELATED COMPLEX; ANIMAL; CLASSIFICATION; EPIDEMIOLOGY; GENETICS; INTESTINE INFECTION; ISOLATION AND PURIFICATION; PARASITOLOGY; PROTOZOAL INFECTION; PROTOZOON;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIPROTOZOAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIARRHEA; EPIDEMIOLOGY, MOLECULAR; HIV INFECTIONS; HUMANS; INTESTINAL DISEASES, PARASITIC; PROTOZOA; PROTOZOAN INFECTIONS;

EID: 48449091705     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.3.337     Document Type: Review

References (175)

1. Wilcox CM. Etiology and evaluation of diarrhoea in AIDS: a global perspective at the millennium. World J. Gastroenterol. 6(2), 177-186 (2000).
2. Tinmouth J, Kandel G, Tomlinson G, Walmsley S, Steinhart HA, Glazier R. Systematic review of strategies to measure HIV-related diarrhea. HIV C1in. Trials 8(3), 155-163 (2007).
3. Lean S, Pollok RC. Management of protozoa-related diarrhea in HIV infection. Expert Rev. Anti Infect. Ther. 3, 455-469 (2003).
4. Wainberg MA, Clotet B. Review: immunologic response to protease inhibitor-based highly active antiretroviral therapy: a review. AIDS Patient Care STDS 21(9), 609-620 (2007).
5. Hunter PR, Hughes S, Woodhouse S et al. Sporadic cryptosporidiosis case-control study with genotyping. Emerg. Infect. Dis. 10, 1241-1249 (2004).
6. Semenza JC, Nichols G. Cryprosporidiosis surveillance and water-borne outbreaks in Europe. Euro. Surveill. 12, E13-EI4 (2007).
7. Caccio, S, Pozzio E. Advances in the epidemiology, diagnosis and treatment of cryptosporidiosis. Expert. Rev. Anti. Infect. Ther. 4, 429-443 (2006).
8. Dillingham RA, Lima AA, Guerrant RL. Cryptosporidiosis: epidemiology and impact. Microbes Infect. 4(10), 1059-1066 (2002).
9. Leoni F, Amax C, Nichols G, Pedraza-Diaz S, McLauchlin J. Genetic analysis of Cryptosporidium from 2414 humans with diarrhoea in England between 1985 and 2000. J. Med. Microbiol. 55, 703-707 (2006)
10. Xiao L, Feng Y. Zoonotic cryptosporidiosis. FEMS Immunol. Med. Microbiol. 52, 309-323 (2008).
11. Chen XM, Keithly JS, Paya CV, LaRusso NF. Cryptosporidiosis. N. Engl. J. Med. 346, 1723 (2002).
12. Yoder JS, Beach MJ. Cryptosporidiosis surveillance - United States, 2003-2005. MMWR Surveill. Summ. 56, 1-10 (2007).
13. Xiao L, Ryan UM. Cryptosporidiosis: an update in molecular epidemiology. Curr. Opin. Infect. Dis. 17(5), 483-490 (2004).
14. Chalmers RM, Ferguson C, Caccio S et al. Direct comparison of selected methods for genetic categorisation of Cryptosporidium parvum and Cryptosporidium hominis species. Int. J. Parasitol. 35, 397-410 (2005).
15. Stroup, SE, Roy S, McHele J et al. Real-time PCR detection and speciation of Cryptosporidium infection using Scorpion probes. J. Med. Microbiol. 55, 1217-1222 (2006).
16. Bandyopadhyay K, Kellar KL, Moura I et al. Rapid microsphere assay for identification of Cryptosporidium hominis and Cryptosporidium parvum in stool and environmental samples. J. Clin. Microbiol. 45, 2835-2840 (2007).
17. Coupe S, Sarfati C, Hamane S, Derouin F. Detection of Cryptosporidium and identification to the species level by nested PCR and restriction fragment length polymorphism. J. Clin. Microbiol. 43, 1017-1023 (2005).
18. Caccio SM. Molecular epidemiology of human cryptosporidiosis. Parasitologia 47, 185-192 (2005).
19. Lake IR, Harrison FC, Chalmers RM et al. Case-control study of environmental and social factors influencing cryptosporidiosis. Eur. J. Epidemiol. 22, 805-811 (2007).
20. Lake IR, Nichols G, Bentham GH, Hunter PR, Kovats SR. Cryptosporidiosis decline after regulation, England and Wales, 1989-2005. Emerg. Infect. Dis. 13, 623-625 (2007).
21. Hunter PR, Hughes S, Woodhouse S et al. Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin. Infect. Dis. 39, 504-510 (2004).
22. Cama, VA, Ross JM, Crawford S et al. Differences in clinical manifestations among Cryptosporidium species and subtypes in HIV-infected persons. J. Infect. Dis. 196, 684-691 (2007).
23. Conteas CN, Berlin OGW, Speck CE, Pandhumas SS, Larivière MJ, Fu C. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am. J. Trop. Med. Hyg. 58, 555-558 (1998).
24. Le Moing V, Bissuel F, Costagliola D et al. Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 12, 1395-1397 (1998).
25. Pozio E, Morales MA. The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol. 21(2), 58-63 (2005).
26. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections Drugs 67(13), 1947-1967 (2007).
27. Cai X, Woods KM, Upton S, Zhu G. Application of quantitative real-time reverse transcription-PCR in assessing drug efficacy against the intracellular pathogen Cryptosporidium parvum in vitro. Antimicrob. Agents Chemother. 49(11), 4437-4442 (2005).
28. Baishanbo A, Gargala G, Duclos C et al. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model. J. Antimicrob. Chemother. 57(2), 353-355 (2006).
29. Abubakar I, Aliyu SH, Arumugam C, Usman NK, Hunter PR. Treatment of cryptosporidiosis in immunocompromised individuals: systematic review and metaanalysis. Br. J. Clin. Pharmacol. 63, 387-393 (2007).
30. Rossignol JF, Hidalgo H, Feregrino M et al. A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans. R. Soc. Trop. Med. Hyg. 92(6), 663-666 (1998).
31. Rossignol JF, Ayoud A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective, randomized, double-blind, placebocontrolled study of nitazoxanide. J. Infect. Dis. 184(1), 103-106 (2001).
32. Amadi B, Mwiya K Musuku J et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomized controlled trial. Lancet 360(9343), 1375-1380 (2002).
33. Rossignol JF, Nitazoxanide in the treatment of acquired immune deficiency syndromerelated cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol. Ther. 24(5), 887-894 (2006).
34. Wittenberg DF, Miller NM, van den Ende J. Spiramycin is not effective in treating cryptosporidium diarrhea in infants: results of a double-blind randomized trial. J. Infect. Dis. 159(1), 131-132 (1989).
35. Woolf GM, Townsend M, Guyatt G. Treatment of cryptosporidiosis with spiramycin in AIDS. An 'N of 1' trial. J. Clin. Gastroenterol. 9(6), 632-634 (1987).
36. Uip DE, Lima ALL, Amato VS, Boulos M, Neto VA, Bem David D. Roxythromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J. Antimicrob. Chemother. 41, S93-S97 (1998).
37. Sprinz E, Mallman R, Barcellos S, Silbert S, Scheatatsky G, Bem David D. AIDS-related cryptosporidial. diarrhoea: an open study with roxythromycin. J. Antimicrob. Chemother. 41 (Suppl.), S85-S91 (1998).
38. Dionisio D, Orsi A, Sterrantino G et al. Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J. Clin. Pathol. 51, 138-142 (1998).
39. Kadappu KK, Nagaraja MY, Rao PV, Shasrty BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad. Med. 48(3), 179-181 (2002).
40. Holmberg SD, Moorin an AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. JAMA 279, 384-386 (1998).
41. Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK; Aids Clinical Trials Group New York Concept Sheet Team 064. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 14, 2889-2893 (2000).
42. Gill EE, Fast NM. Assessing the microsporidia-fungi relationship: combined phylogenetic analysis of eight genes. Gene 375, 103-109 (2006).
43. Abreu-Acosta N, Lorenzo-Morales J, Leal-Guio Y et al. Enteracytozoon bieneusi (microsporidia) in clinical samples from immunocompetent individuals in Tenerife, Canary Islands, Spain. Trans. R. Soc. Trop. Med. Hyg. 99(11), 848-855 (2005).
44. Didier ES, Maddry JA, Brindley PJ et al. Therapeutic strategies for human microsporidia infections. Expert Rev. Anti Infect. Ther. 3, 419-434 (2005).
45. Chacin-Bonilla L, Panunzio AP, Monsalve-Castillo FM et al. Microsporidiosis in Venezuela: prevalence of intestinal microsporidiosis and its contribution to diarrhea in a group of human immunodeficiency virus-infected patients from Zuha state. Am. J. Trop. Med. Hyg. 74(3), 482-486 (2006).
46. Endeshaw T, Kebede A, Verweij JJ et al. Intestinal microsporidiosis in diarrheal patients infected with human immunodeficiency virus-1 in Addis Ababa, Ethiopia. Jpn J. Infect. Dis. 59(5), 306-310 (2006).
47. Espern A, Morio F, Miegeville M et al. Molecular study of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon intestinalis among human immunodeficiency virus-infected patients from two geographical areas: Niamey, Niger, and Hanoi, Vietnam. J. Clin. Microbiol. 45(9), 2999-3002 (2007).
48. Samie A, Obi CL, Tzipori S et al. Microsporidiosis in South Africa: PCR detection in stool samples of HIV-positive and HIV-negative individuals and school children in Vhembe district, Limpopo province. Trans. R. Soc. Trop. Med. Hyg. 101(6), 547-554 (2007).
49. Tumwine JK, Kekitiinwa A, Bakeera-Kitaka S et al. Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am. J. Trop. Med. Hyg. 73(5), 9211-925 (2005).
50. Kotler DP, Orenstein JM. Prevalence of intestinal microsporidiosis in HIV-infected individuals referred for gastroenterological evaluation. Am. J. Gastroenterol. 89(11), 1998-2002 (1994).
51. Molina JM, Sarfati C, Beauvais B et al. Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features. J. Infect. Dis. 167(1), 217-221 (1993).
52. Leelayoova S, Subrungruang I, Rangsin R et al. Transmission of Enterocytozoon bieneusi genotype a in a Thai orphanage. Am. J. Trop. Med. Hyg. 73, 104-107 (2005).
53. Bern C, Kawai V, Vargas D et al. The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru. J. Infect. Dis. 191(10), 1658-1664. (2005).
54. Breton J, Bart-Delabesse E, Biligui S et al. New highly divergent rRNA sequence among biodiverse genotypes of Enterocytozoon bieneusi strains isolated from humans in Gabon and Cameroon. J. Clin. Microbiol. 45(8), 2580-2589 (2007).
55. Thellier M, Breton J. Enterocytozoon bieneusi in human and animals, focus on laboratory identification and molecular epidemiology. Parasite 15 (2008) (In Press).
56. Botterel F, Minozzi C, Vittecoq D et al. Pulmonary localization of Enterocytozoon bieneusi in an AIDS patient: case report and review. J. Clin. Microbiol. 40(12), 4800-4801 (2002).
57. Pol S, Romana CA, Richard S et al. Microsporidia infection in patients with the human immunodeficiency virus and unexplained cholangitis. N. Engl. J. Med. 328(2), 95-99 (1993).
58. Kotler DP, Orenstein JM. Clinical syndromes associated with microsporidiosis. Adv. Parasit. 40, 322-349 (1998).
59. Garcia LS. Laboratory identification of the microsporidia. J. Clin. Microbiol. 40, 1892-1901 (2002).
60. Sheoran AS, Feng X, Singh I et al. Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin. Diagn. Lab. Immunol. 12, 1109-1113 (2005).
61. Mo L, Drancourt M. Monoclonal antibodies for specific detection of Encephalitozoon cuniculi. Clin. Diagn. Lab. Immunol. 11, 1060-1063 (2004).
62. Menotti J, Cassinat B, Porcher R et al. Development of a real-time polymerasechain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stools specimens from immunocompromised patients with intestinal microsporidiosis. J. Infect. Dis. 187(9), 1469-1474 (2003).
63. Molina JM, Tourneur M, Sarfati C et al. Fumagillin treatment of intestinal microsporidiosis. N. Engl. J. Med. 346(25), 1963-1969 (2002).
64. Molina JM, Chastang C, Goguel J et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J. Infect. Dis. 177(5), 1373-1377 (1998).
65. Menotti J, Santillana-Hayat M, Cassinat B et al. Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture- quantitative PCR assay. Antimicrob Agents Chemother. 49(6), 2362-2366 (2005).
66. Miao YM, Awad-El-Kariem FM, Franzen C et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25(2), 124-129 (2000).
67. Lafaurie M, Sarfati C, Menotti J et al. Remission of disseminated infection caused by Encephalocytozoon intestinalis with highly active antiretroviral therapy. AIDS 17(4), 640-641 (2003).
68. Didier ES, Stovall ME, Green LC et al. Epidemiology of microsporidiosis: sources and modes of transmission. Vet. Parasitol. 126, 145-166 (2004).
69. Graczyk TK, Sunderland D, Tamang L et al. Quantitative evaluation of the impact of bather density on levels of human-virulent microsporidian spores in recreational water. Appl. Environ. Microbiol. 73(13), 4095-4099 (2007).
70. Certad G, Arenas-Pinto A, Pocatefra L et al. Isosporiasis in Venezuelan adults infected with human immunodeficiency virus: clinical characterization. Am. J. Trop. Med. Hyg. 69(2), 217-222 (2003).
71. Escobedo AA, Núñez FA. Prevalence of intestinal parasites in Cuban acquired immunodeficiency syndrome (AIDS) patients. Acta Trop. 72(1), 125-130 (1999).
72. Lagrange-Xélot M, Porcher R, Sarfati C et al. Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med. 9(2), 126-130(2008)
73. Lebbad M, Norrgren H, Nauclér A et al. Intestinal parasites in HIV-2 associated AIDS cases with chronic diarrhoea in Guinea-Bissau. Acta Trop. 80(1), 45-49 (2001).
74. Sarfati C, Bourgeois A, Menotti J et al. Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study. Am. J. Trop. Med. Hyg. 74(1), 162-164 (2006).
75. Silva CV, Ferreira MS, Borges AS et al. Intestinal parasitic infections in HIV/AIDS patients: experience at a teaching hospital in central Brazil. Scand. J. Infect. Dis. 37(3), 211-215 (2005).
76. Wiwanitkit V. Intestinal parasitic infections in Thai HIV-infected patients with different immunity status. BMC Gastroenterol. 1, 3 (2001).
77. Guiguet M, Furco A, Tattevin P et al. Database on HIV Clinical Epidemiology Group. HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV. HIV Med. 8(2), 124-130 (2007).
78. Forthal DN, Guest SS. Isospara belli enteritis in three homosexual men. Am. J. Trop. Med. Hyg. 33(6), 1060-1064 (1984).
79. DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr. Clinical manifestations and therapy of Isorpora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 315(2), 87-90 (1986).
80. French AL, Beaudet LM, Benator DA et al. Cholecystectomy in patients with AIDS: clinicopathologic correlations in 107 cases. Clin. Infect. Dis. 21, 852-858 (1995).
81. Gonzalez-Dominguez J, Roldan R, Villanueva JL et al. Isospora belli reactive arthritis in a patient with AIDS. Ann. Rheum. Dis. 53, 618-619 (1994).
82. Restrepo C, Macher AM, Radany EH. Disseminated extraintestinal isosporiasis in a patient with acquired immune deficiency syndrome. Am. J. Clin. Pathol. 87, 536-542 (1987).
83. Lindsay DS, Dubey JP. Toivio-Kinnucan MA et al. Examination of extraintestinal tissue cysts of Isospora belli. J. Parasitol. 83, 620-625 (1997).
84. Frenkel JK, Silva MB, Saldanha J et al. Isospora belli infection: observation of unicellular cysts in mesenteric lymphoid tissues of a Brazilian patient with AIDS and animal inoculation. J. Eukaryot. Microbiol. 50(Suppl.), 682-684 (2003).
85. Pape JW, Verdier RI, Johnson WD Jr. Treatment and prophylaxis of Isorpora belli infection in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 320, 1044-1047 (1989).
86. Ng E, Markell EK, Fleming RL et al. Demonstration of Irospora belli by acid-fast stain in a patient with acquired immune deficiency syndrome. J. Clin. Microbiol. 20, 384-386 (1984).
87. Berlin OG, Conteas CN, Sowerby TM. Detection of Isospora in the stools of AIDS patients using a new rapid autofluorescence technique. AIDS 10, 442-443 (1996).
88. Franzen C, Müller A, Salzberger B et al. Uvitex 2B stain for the diagnosis of Isospora belli infections in patients with the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 120(11), 1023-1025 (1996).
89. Verdier RI, Fitzgerald DW, Johnson WD Jr et al. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann. Intern. Med. 132(11), 885-888 (2000).
90. Weiss LM, Perlman DC, Sherman J et al. Isospora belli infection: treatment with pyrimethamine. Ann. Intern. Med. 109, 474-475 (1988).
91. Kayembe K, Desmet P, Henry MC et al. Diclazuril for Isospora belli infection in AIDS. Lancet 1, 1397-1398 (1989).
92. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56, 637-639 (1997).
93. Musey KL, Chidiac C, Beaucaire G et al. Effectiveness of roxithromyrin for treating Isorpora belli infection. J. Infect. Dis. 158, 646 (1988).
94. Dionisio D, Sterrantino G, Meli M et al. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. AIDS 10, 1301-1302 (1996).
95. Ashford RW. Occurrence of an undescribed coccidian in man in Papua New Guinea. Ann. Trop. Med. Parasitol. 73(5), 497-500 (1979).
96. Blans MC, Ridwan BU, Verweij JJ et al. Cyclosporiasis outbreak, Indonesia. Emerg. Infect. Dis. 11(9), 1453-1455 (2005).
97. Herwaldt BL. Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin. Infect. Dis. 31, 1040-1057 (2000).
98. Kumar SS, Ananthan S, Lakshmi P. Intestinal parasitic infection in HIV infected patients with diarrhoea in Chennai. Indian J. Med. Microbiol. 20(2), 88-91 (2002).
99. Manatsathit S, Tansupasawasdikul S, Wanachiwanawin D et al. Causes of chronic diarrhea in patients with AIDS in Thailand: a prospective clinical and microbiological study. J. Gastroenterol. 31(4), 533-537 (1996).
100. Mansfield LS, Gajadhar AA. Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet. Parasitol. 126(1-2), 73-90 (2004).
101. Pape JW, Verdier RI, Boncy M et al. Cyclospora infection in adults infected with HIV: clinical manifestations, treatment and prophylaxis. Ann. Intern. Med. 121, 654-657 (1994).
102. de Gorgolas M, Fortes J, Fernadez Guerrero ML. Cyclospora cayetanensis cholecystitis in a patient with AIDS. Ann. Intern. Med. 134, 166 (2001).
103. Zar FA, El-Bayoumi E, Yungbluth MM. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin. Infect. Dis. 33(12), E140-E141 (2001).
104. Eberhard ML, Pieniazek NJ, Arrowood MJ. Laboratory diagnosis of Cyclospora infections. Arch. Pathol. Lab. Med. 121, 792-797 (1997).
105. Dixon BR, Bussey JM, Parrington LJ et al. Detection of Cyclospora cayetanensis cocysts in human fecal specimens by flow cytometry. J. Clin. Microbiol. 43, 2375-2379 (2005).
106. Kimura K, Kumar Rai S, Takemasa K et al. Comparison of three microscopic techniques for diagnosis of Cyclospora cayetanensis. FEMS Microbiol. Lett. 238(1), 263-266 (2004).
107. Pieniazek NJ, Slemenda SB, da Silva AJ et al. PCR confirmation of infection with Cyclospora cayetanensis. Emerg. Infect. Dis. 2, 357-359 (1996).
108. Hussein EM, El-Moamly AA, Dawoud HA et al. Real-time PCR and flow cytometry in detection of Cyclospora oocysts in fecal samples of symptomatic and asymptomatic pediatrics patients. J. Egypt. Soc. Parasitol. 37(1), 151-170 (2007).
109. Verweij JJ, Laeijendecker D, Brienen EAT et al. Detection of Cyclospora cayetanensis in travellers returning from the tropics and subtropics using microscopy and realtime PCR. Int. J. Med. Microbiol. 293, 199-202 (2003).
110. Ortega RY, Sterling CR, Gilman RH, Cama VA, Diaz F. Cyclospora species - a new protozoan pathogen of humans. N. Engl. J. Med. 328, 1308-1312 (1993).
111. Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by 'amitochondriate' protozoan parasites. Clin Microbiol Rev. 20(1), 164-187 (2007).
112. Aronson NE, Cheney C, Rholl V et al. Biliary giardiasis in a patient with human immunodeficiency virus. J. Clin. Gastroenterol. 33, 167-170 (2001).
113. Weiss LM, Perlman DC, Sherman J et al. Isorpora belli infection: treatment with pyrimethamine. Ann. Intern. Med. 109, 474-475 (1988).
114. Kayembe K, Desmet P, Henry MC et al. Diclazuril for Isospora belli infection in AIDS. Lancet 1, 1397-1398 (1989).
115. Doumbo O, Rossignol JF, Pichard E et al. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa. Am. J. Trop. Med. Hyg. 56, 637-639 (1997).
116. Musey KL, Chidiac C, Beaucaire G et al. Effectiveness of roxithromyrin for treating Isorpora belli infection. J. Infect. Dis. 158, 646 (1988).
117. Dionisio D, Sterrantino G, Meli M et al. Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. AIDS 10, 1301-1302 (1996).
118. Ashford RW. Occurrence of an undescribed coccidian in man in Papua New Guinea. Ann. Trop. Med. Parasitol. 73(5), 497-500 (1979).
119. Blans MC, Ridwan BU, Verweij JJ et al. Cyclosporiasis outbreak, Indonesia. Emerg. Infect. Dis. 11(9), 1453-1455 (2005).
120. Herwaldt BL. Cyclospora cayetanensis: a review, focusing on the outbreaks of cyclosporiasis in the 1990s. Clin. Infect. Dis. 31, 1040-1057 (2000).
121. Kumar SS, Ananthan S, Lakshmi P. Intestinal parasitic infection in HIV infected patients with diarrhoea in Chennai. Indian J. Med. Microbiol. 20(2), 88-91 (2002).
122. Manatsathit S, Tansupasawasdikul S, Wanachiwanawin D et al. Causes of chronic diarrhea in patients with AIDS in Thailand: a prospective clinical and microbiological study. J. Gastroenterol. 31(4), 533-537 (1996).
123. Mansfield LS, Gajadhar AA. Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet. Parasitol. 126(1-2), 73-90 (2004).
124. Pape JW, Verdier RI, Boncy M et al. Cyclospora infection in adults infected with HIV: clinical manifestations, treatment and prophylaxis. Ann. Intern. Med. 121, 654-657 (1994).
125. de Gorgolas M, Fortes J, Fernadez Guerrero ML. Cyclospora cayetanensis cholecystitis in a patient with AIDS. Ann. Intern. Med. 134, 166 (2001).
126. Zar FA, El-Bayoumi E, Yungbluth MM. Histologic proof of acalculous cholecystitis due to Cyclospora cayetanensis. Clin. Infect. Dis. 33(12), E140-E141 (2001).
127. Eberhard ML, Pieniazek NJ, Arrowood MJ. Laboratory diagnosis of Cyclospora infections. Arch. Pathol. Lab. Med. 121, 792-797 (1997).
128. Dixon BR, Bussey JM, Parrington LJ et al. Detection of Cyclospora cayetanensis cocysts in human fecal specimens by flow cytometry. J. Clin. Microbiol. 43, 2375-2379 (2005).
129. Kimura K, Kumar Rai S, Takemasa K et al. Comparison of three microscopic techniques for diagnosis of Cyclospora cayetanensis. FEMS Microbiol. Lett. 238(1), 263-266 (2004).
130. Pieniazek NJ, Slemenda SB, da Silva AJ et al. PCR confirmation of infection with Cyclospora cayetanensis. Emerg. Infect. Dis. 2, 357-359 (1996).
131. Hussein EM, El-Moamly AA, Dawoud HA et al. Real-time PCR and flow cytometry in detection of Cyclospora oocysts in fecal samples of symptomatic and asymptomatic pediatrics patients. J. Egypt. Soc. Parasitol. 37(1), 151-170 (2007).
132. Verweij JJ, Laeijendecker D, Brienen EAT et al. Detection of Cyclospora cayetanensis in travellers returning from the tropics and subtropics using microscopy and realtime PCR. Int. J. Med. Microbiol. 293, 199-202 (2003).
133. Ortega RY, Sterling CR, Gilman RH, Cama VA, Diaz F. Cyclospora species - a new protozoan pathogen of humans. N. Engl. J. Med. 328, 1308-1312 (1993).
134. Ali V, Nozaki T. Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by 'amitochondriate' protozoan parasites. Clin Microbiol Rev. 20(1), 164-187 (2007).
135. Aronson NE, Cheney C, Rholl V et al. Biliary giardiasis in a patient with human immunodeficiency virus. J. Clin. Gastroenterol. 33, 167-170 (2001).
136. Nash TE, Ohl CA, Thomas E et al. Treatment of patients with refractory giardiasis. Clin. Infect. Dis. 33, 22-28 (2001).
137. Lemee V, Zaharia I, Nevez G et al. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J. Antimicrob. Chemother. 46, 819-821 (2000).
138. Adagu IS, Nolder D, Warhurst DC et al. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother. 49, 103-111 (2002).
139. Abboud P, Lemee V, Gargala G et al. Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. 32, 1792-1794 (2001).
140. Dunn LA, Andrews KT, McCarthy JS et al. The activity of protease inhibitors against Giandia duodenalis and metronidazole-resistant Trichomonas vaginalis. Int. J. Antimicrob. Agents. 29(1), 98-102 (2007).
141. Lowther SA, Dworkin MS, Hanson DL. Entamoeba histolytica/Entamoeba dispar infections in human immunodeficiency virus-infected patients in the United States. Clin. Infect. Dis. 30, 955-959 (2000).
142. Hung CC, Chen PJ, Hsieh SM et al. Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection. AIDS 3, 2421-2428 (1999).
143. Morán P, Ramos F, Ramiro M et al. Infection by human immunodeficiency virus-1 is not a risk factor for amebiasis. Am. J. Trop. Med. Hyg. 73(2), 296-300 (2005).
144. Fotedar R, Stark D, Beebe N et al. Laboratory diagnostic techniques for Entamoeba species. Clin. Microbiol. Rev. 20(3), 511-532 (2007).
145. Salles JM, Salles MJ, Moraes LA et al. Invasive amebiasis: an update on diagnosis and management. Expert Rev. Anti Infect. Ther. 5(5), 893-901 (2007).
146. Rossignol JF, Kabil SM, El-Gohary Y et al. Nitazoxanide in the treatment of amoebiasis. Trans. R., Soc. Trop. Med. Hyg. 101(10), 1025-1031 (2007).
147. Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J. Dientamoebiasis: clinical importance and recent advances. Trends Parasitol. 22(2), 92-96 (2006).
148. Méndez OC, Szmulewicz G, Menghi C, Torres S, González G, Gatta C. Comparison of intestinal parasite infestation indexes among HIV positive and negative populations. Medicina (B. Aires). 54(4), 307-310 (1994).
149. Johnson EH, Windsor JJ, Clark CG. Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis. Clin. Microbiol. Rev. 17(3), 553-570 (2004).
150. Tan KSW. Blastocystis spp. In: Emerging Protozoan Pathogens. NA Khan (Ed.) Taylors and Francis Group, NY, USA 153-189 (2007).
151. Tan KS. Blastocystis in humans and animals: new insights using modern methodologies. Vet. Parasitol. 126(1-2), 121-144 (2004).
152. Brites C, Barberino MG, Bastos MA et al. Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. Braz. J. Infect. Dis. 1, 91-94 (1997).
153. Albrecht H, Stellbrink HJ, Koperski K et al. Blastocystis hominis in human immunodeficiency virus-related diarrhea. Scand. J. Gastroenterol. 30, 909-914 (1995).
154. Moghaddam DD, Ghadirian E, Azami M. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/ sulfamethoxazole. Parasitol. Res. 96(4), 273-275 (2005).
155. Rossignol JF, Kabil SM, Said M et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. 3(10), 987-991 (2005).
156. Stenzel DJ, Borrham PF. Blastocystis hominis revisited. Clin. Microbiol. Rev. 9(4), 563-584 (1996).
157. Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection. syndrome: an emerging global infectious disease. Trans. R. Soc. Trop. Med. Hyg. 102(4), 314-318 (2008).
158. Lucas SB. Missing infections in AIDS. Trans. Roy. Soc. Trop. Med. Hyg. 84 (Suppl.), S34-S38 (1990).
159. Viney ME, Brown M, Omoding NE et al. Why does HIV infection not lead to disseminated strongyloidiasis? J. Infect. Dis. 190(12), 2175-2180 (2004).
160. Monkemuller KE, Call SA, Lazenby AJ, Wilcox CM. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy. Am. J. Gastroenterol. 95(2), 457-462 (2000).
161. Babiker A, Darbyshire J, Pezzotti P et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int. J. Epidemiol. 31(5), 951-958 (2002).
162. 3, Am. J. Gastroenterol. 95(11), 3142-3146 (2000).
163. Schmidt W, Wahnschaffe U, Schafer M et al. Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology 120, 984-987 (2001).
164. Mele R., Gomez Morales MA, Tosini F, Pozio E. Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. Int. J. Parasitol. 33(7), 757-764 (2003).
165. Homers V. Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. J. Antimicrob. Chemother. 52, 359-364 (2003).
166. Coombs G.H, Goldberg DE, Klemba M et al. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17, 532-537 (2001).
167. Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346(26), 2039-2046 (2002).
168. Plasencia LD, Socas MM, Valls RA et al. Terminal ileitis as a manifestation of immune reconstitution syndrome following HAART. AIDS 20, 1903-1905 (2006).
169. Gajdatsy AD, Tay-Kearney ML. Microsporidial keratoconjunctivitis after HAART. Clin. Experiment. Ophthalmol. 29(5), 327-329 (2001).
170. Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr. Opin. Infect. Dis. 20(5), 482-488 (2007).
171. Maynart M, Lievre L, Sow PS et al. Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal. J. Acquir. Immune Defic. Syndr. 26, 130-136 (2001).
172. Dworkin MS, Williamson J, Jones JL et al. Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin. Infect. Dis. 33, 393-398 (2001).
173. Anglaret X, Chêne G, Attia A et al. Early chemotherapy with trimethoprim-sulfamethoxazole for HIV-1 infected adults in Abidjan, Côte d'Ivoire: a randomized trial. Lancet 353, 1463-1468 (1999).
174. Kelly P, Lungu F, Keane E et al. Albendazole chemotherapy for treatment of diarrhea in patients with AIDS in Zambia: a randomised double blind controlled trial. Br. Med. J. 312, 1187-1191 (1996).
175. Zulu I, Kelly P, Njobvu L et al. Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 21(6), 757-763 (2005).